In this study, we designed several chloroquine derivatives—2‐methyl‐7‐chloroquinoline and methylcarbazole hybrid compounds that have certain BRAF‐mutant melanoma inhibitory activities—and identified the most active compound, lj‐2‐66 (Table 1). Here, BRAF is linked to melanoma.